ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1939

Risk of Cardiovascular Outcomes in Patients Treated with Tofacitinib: First Results from the Safety of TofAcitinib in Routine Care Patients with Rheumatoid Arthritis (STAR-RA) Study

Farzin Khosrow-Khavar, Seoyoung Kim, Hemin Lee, Su Been Lee and Rishi Desai, Brigham and Women's Hospital, Boston, MA

Meeting: ACR Convergence 2021

Keywords: Cardiovascular, Disease-Modifying Antirheumatic Drugs (Dmards), Pharmacoepidemiology, rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 9, 2021

Session Title: Abstracts: RA – Treatments I: Safety & Harms (1939–1942)

Session Type: Abstract Session

Session Time: 4:00PM-4:15PM

Background/Purpose: Recent reports from a post-marketing safety trial, “ORAL Surveillance”, indicated an increased risk of cardiovascular (CV) outcomes in RA patients treated with tofacitinib. Thus, the aim of this study was to examine the risk of CV outcomes associated with tofacitinib, compared with tumor necrosis factor inhibitors (TNFI), in patients with RA.

Methods: Using U.S. claims data from ‘Optum’ Clinformatics (2012-2020), IBM ‘MarketScan’ (2012-2018), and Medicare (parts A, B, and D, 2012-2017) databases, we created two study cohorts of RA patients initiating treatment with tofacitinib or TNFI: 1) A restrictive “RCT-duplicate cohort” mimicking inclusion/exclusion criteria of the ORAL Surveillance trial to calibrate our findings against trial results, 2) a broader “real-world evidence (RWE) cohort” including representative population from routine care. Patients were followed from treatment initiation for study outcomes until treatment discontinuation or switch, insurance disenrollment, death, or end of the study period. The primary composite CV outcome, was defined using inpatient claims for myocardial infarction or stroke. Cox proportional hazards models with propensity score fine-stratification weighting were used to generate hazard ratios (HR) and 95% confidence intervals (CI) and accounted for over 60 potential confounders in each of the datasets. Fixed effects models with inverse variance were used to pool database-specific effect estimates. Secondary analysis was conducted by baseline cardiovascular disease (RWE cohorts only).

Results: In RWE study population, 28,568, 34,083, and 39,612 patients were identified from Optum, MarketScan, and Medicare, respectively, of whom 13.2%, 15.6%, and 9.5% initiated treatment on tofacitinib. The mean age was 55, 53, and 72 years in Optum, MarketScan, and Medicare, respectively. In RWE cohort, 13% of patients in Optum, 10% in MarketScan, and 31% in Medicare had a history of cardiovascular disease. The crude incidence rates of the primary CV endpoint per 100 person-years (95% CI) for tofacitinib and TNFI users were 0.73 (0.47-1.09) and 0.61 (0.51-0.72) in Optum; 0.75 (0.52-1.05) and 0.52 (0.44-0.61) in MarketScan; and 2.14 (1.66-2.70) and 1.86 (1.71-2.02) in Medicare. Overall, in the RWE cohort, the pooled HR (95% CI) for CV outcomes comparing tofacitinib with TNFI was 1.01 (0.83-1.23). Results from the RCT-duplicate cohort were in alignment with reports from the ORAL Surveillance trial (pooled HR: 1.24, 95% CI: 0.90-1.69 vs trial: 1.33, 95% CI: 0.91-1.94). Among RWE patients with baseline cardiovascular disease, the pooled HR (95% CI) was 1.27 (0.95-1.70). Consistent results were observed across other secondary and sensitivity analyses.

Conclusion: This multi-database large population-based study did not find evidence for an increased risk of CV outcomes with tofacitinib, in comparison with TNFI, in the overall RA patient population treated in the real-world setting. However, similar to the reported results from ORAL Surveillance trial, tofacitinib, in comparison with TNFI, was associated with an increased, but statistically non-significant, risk of CV outcomes in RA patients with CV risk factors or a history of cardiovascular disease.

Figure. Risk of composite CV outcomes when comparing tofacitinib with TNF inhibitors (reference) in patients with RA.


Disclosures: F. Khosrow-Khavar, None; S. Kim, AbbVie, 5, Roche, 5, Pfizer, 5, Bristol-Myers Squibb, 5; H. Lee, None; S. Lee, None; R. Desai, Bayer, 5, Vertex Pharmaceuticals, 5, Novartis, 5.

To cite this abstract in AMA style:

Khosrow-Khavar F, Kim S, Lee H, Lee S, Desai R. Risk of Cardiovascular Outcomes in Patients Treated with Tofacitinib: First Results from the Safety of TofAcitinib in Routine Care Patients with Rheumatoid Arthritis (STAR-RA) Study [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/risk-of-cardiovascular-outcomes-in-patients-treated-with-tofacitinib-first-results-from-the-safety-of-tofacitinib-in-routine-care-patients-with-rheumatoid-arthritis-star-ra-study/. Accessed March 28, 2023.
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/risk-of-cardiovascular-outcomes-in-patients-treated-with-tofacitinib-first-results-from-the-safety-of-tofacitinib-in-routine-care-patients-with-rheumatoid-arthritis-star-ra-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences